Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Case ReportsCase Reports

Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report

HIROKI BAMBA, SATOSHI YAMAMOTO, KEITA HIGA, KOICHIRO KUROKAWA, SANJI KANAOKA and KAZUYOSHI NAKAMURA
Anticancer Research March 2026, 46 (3) 1747-1753; DOI: https://doi.org/10.21873/anticanres.18069
HIROKI BAMBA
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI YAMAMOTO
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: satoshi.ym0809{at}gmail.com
KEITA HIGA
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHIRO KUROKAWA
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SANJI KANAOKA
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYOSHI NAKAMURA
Department of Urology, Kimitsu Chuo Byoin, Kisarazu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 46 (3)
Anticancer Research
Vol. 46, Issue 3
March 2026
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Ed Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report
HIROKI BAMBA, SATOSHI YAMAMOTO, KEITA HIGA, KOICHIRO KUROKAWA, SANJI KANAOKA, KAZUYOSHI NAKAMURA
Anticancer Research Mar 2026, 46 (3) 1747-1753; DOI: 10.21873/anticanres.18069

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report
HIROKI BAMBA, SATOSHI YAMAMOTO, KEITA HIGA, KOICHIRO KUROKAWA, SANJI KANAOKA, KAZUYOSHI NAKAMURA
Anticancer Research Mar 2026, 46 (3) 1747-1753; DOI: 10.21873/anticanres.18069
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Case Report
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review
  • ABSTRACTS OF THE JOINT INTERNATIONAL SYMPOSIA “VITAMIN D IN PREVENTION AND THERAPY” AND “BIOLOGIC EFFECTS OF LIGHT”
  • Unexpected Modifications to Surgical Plans in Computer-assisted Mandibulectomy With Fibula Free-flap Reconstruction: A Five-case Series
Show more Case Reports

Keywords

  • Urothelial carcinoma
  • enfortumab vedotin
  • pembrolizumab
  • esophageal ulcer
  • immune-related adverse events
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire